SCHEMBL30925440

SCHEMBL30925440

CCn1ccnc1S(=O)(=O)Nc1cccc2cccnc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLO1 Q04760 7/20 0.56
▸ HTT P42858 2/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ SLC40A1 Q9NP59 13/20 0.55
▸ TDP1 Q9NUW8 6/20 0.55
▸ AGTR1 P30556 2/20 0.55
▸ NFKBIA P25963 2/20 0.55
▸ G6PD P11413 1/20 0.55
▸ METAP2 P50579 1/20 0.55
▸ METAP1 P53582 1/20 0.55
▸ PAX8 Q06710 1/20 0.55
▸ ATM Q13315 1/20 0.55
▸ KMT2A Q03164 5/20 0.55
▸ MITF O75030 1/20 0.55
▸ S1PR4 O95977 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ S1PR1 P21453 1/20 0.55
▸ OPRK1 P41145 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27214285 1.00 GLO1 (0.56) GLO1HTTALOX15SLC40A1TDP1
SCHEMBL30925542 0.87 SLC40A1 (0.56) GLO1HTTSLC40A1TDP1AGTR1
SCHEMBL30925514 0.86 SLC40A1 (0.61) HTTSLC40A1TDP1AGTR1NFKBIA
SCHEMBL27214206 0.86 SLC40A1 (0.59) GLO1SLC40A1TDP1KMT2ACKS1B
SCHEMBL30925560 0.86 SLC40A1 (0.59) GLO1SLC40A1TDP1KMT2ACKS1B
SCHEMBL29800997 0.85 SLC40A1 (0.60) GLO1HTTSLC40A1TDP1AGTR1
SCHEMBL26964402 0.85 SLC40A1 (0.60) GLO1HTTSLC40A1TDP1AGTR1
SCHEMBL30925557 0.84 SLC40A1 (0.47) SLC40A1TDP1KMT2AMEN1
SCHEMBL30925508 0.84 SLC40A1 (0.45) GLO1SLC40A1
SCHEMBL27214324 0.84 SLC40A1 (0.47) SLC40A1TDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 GLO1 3779/4885HTT 708/4885ALOX15 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback